Human genetic investigation of TMPRSS6 as a therapeutic target for liver disease: efficacy and safety liabilities
Abstract
Background & Aims: Disease-modifying therapies for steatohepatitis and fibrosis remain limited. Matriptase-2 (TMPRSS6), a serine protease suppressing hepcidin to regulate iron homeostasis, is under clinical investigation for iron overload, and preclinical evidence suggests its inhibition may attenuate metabolic liver disease. Whether these effects translate to humans remains unknown. Methods: We proxied TMPRSS6 inhibition using the missense variant rs855791, weighted on circulating hepcidin. Using Mendelian randomization (MR), we assessed effects on (1) magnetic resonance imaging-derived liver phenotypes, including corrected T1 (cT1) and proton density fat fraction (PDFF), liver enzymes and clinical liver outcomes; (2) cardiometabolic endpoints; (3) 2,940 plasma proteins; (4) clinical biomarkers; and (5) 2,272 disease endpoints. Colocalization and mediation analyses were used to characterize mechanisms. Results: Genetically proxied TMPRSS6 inhibition was associated with lower liver iron content ({beta} = -2.50, P<0.001) and higher cT1 ({beta} = 1.59, P<0.001), with colocalization indicating a shared causal signal. No association was observed with PDFF, liver volume, NAFLD, cirrhosis or hepatocellular carcinoma. Genetically proxied TMPRSS6 inhibition was also associated with lower C-reactive protein ({beta} = -0.17, P<0.001), higher LDL cholesterol ({beta} = 0.22, P<0.001) and higher coronary artery disease (CAD) risk (OR = 1.59, P<0.001), with weak colocalization of CAD with hepcidin (PP.H = 0.56) and LDL cholesterol (PP.H = 0.48). Mediation analysis suggested LDL cholesterol may account for approximately 21% (95% CI 9% to 34%) of the CAD association. Conclusions: Human genetic evidence supports hepatic iron lowering by TMPRSS6 inhibition, but not an effect on steatosis. Higher cT1, without concordant associations with clinical liver outcomes, may reflect reduced hepatic iron rather than worsening fibroinflammation. The CAD signal, partly mediated by LDL cholesterol, warrants careful consideration in trial design.
Related
- Divergent genetic mediator signatures of adiposity-related metabolic liabilities and coronary artery disease.
- Hypervirulent Klebsiella pneumoniae Infections in Vancouver, Canada: A Clinical, Microbiological, and Genetic Retrospective Investigation
- Preliminary Investigation of Maternal and Offspring Genetic Effects of the DBH Gene in Probands with Schizophrenia and Their Relatives
- Temporal and therapeutic confounders in predicting efficacy of immunotherapy rechallenge via baseline intratumoral tertiary lymphoid structures.
- Efficacy of a smartphone digital therapeutic (re-R) for post-total knee arthroplasty rehabilitation: study protocol for a single-center randomized controlled trial in the Republic of Korea
BibTeX
@misc{dib2026human,
title = {{Human genetic investigation of TMPRSS6 as a therapeutic target for liver disease: efficacy and safety liabilities}},
author = {M.-J. Dib and M. Vujkovic and S. Burgess and T. Dutta and I. Tzoulaki and A. Dehghan and H. Yaghootkar and D. Meena},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.29.26366887},
url = {https://www.medrxiv.org/content/10.64898/2026.10.29.26366887v1},
note = {CC BY-ND},
}
RIS
TY - UNPB
TI - Human genetic investigation of TMPRSS6 as a therapeutic target for liver disease: efficacy and safety liabilities
AU - M.-J. Dib
AU - M. Vujkovic
AU - S. Burgess
AU - T. Dutta
AU - I. Tzoulaki
AU - A. Dehghan
AU - H. Yaghootkar
AU - D. Meena
PY - 2026
DA - 2026/10/29
PB - medRxiv
DO - 10.64898/2026.10.29.26366887
UR - https://www.medrxiv.org/content/10.64898/2026.10.29.26366887v1
AB - Background & Aims: Disease-modifying therapies for steatohepatitis and fibrosis remain limited. Matriptase-2 (TMPRSS6), a serine protease suppressing hepcidin to regulate iron homeostasis, is under clinical investigation for iron overload, and preclinical evidence suggests its inhibition may attenuate metabolic liver disease. Whether these effects translate to humans remains unknown. Methods: We proxied TMPRSS6 inhibition using the missense variant rs855791, weighted on circulating hepcidin. Using Mendelian randomization (MR), we assessed effects on (1) magnetic resonance imaging-derived liver phenotypes, including corrected T1 (cT1) and proton density fat fraction (PDFF), liver enzymes and clinical liver outcomes; (2) cardiometabolic endpoints; (3) 2,940 plasma proteins; (4) clinical biomarkers; and (5) 2,272 disease endpoints. Colocalization and mediation analyses were used to characterize mechanisms. Results: Genetically proxied TMPRSS6 inhibition was associated with lower liver iron content ({beta} = -2.50, P<0.001) and higher cT1 ({beta} = 1.59, P<0.001), with colocalization indicating a shared causal signal. No association was observed with PDFF, liver volume, NAFLD, cirrhosis or hepatocellular carcinoma. Genetically proxied TMPRSS6 inhibition was also associated with lower C-reactive protein ({beta} = -0.17, P<0.001), higher LDL cholesterol ({beta} = 0.22, P<0.001) and higher coronary artery disease (CAD) risk (OR = 1.59, P<0.001), with weak colocalization of CAD with hepcidin (PP.H = 0.56) and LDL cholesterol (PP.H = 0.48). Mediation analysis suggested LDL cholesterol may account for approximately 21% (95% CI 9% to 34%) of the CAD association. Conclusions: Human genetic evidence supports hepatic iron lowering by TMPRSS6 inhibition, but not an effect on steatosis. Higher cT1, without concordant associations with clinical liver outcomes, may reflect reduced hepatic iron rather than worsening fibroinflammation. The CAD signal, partly mediated by LDL cholesterol, warrants careful consideration in trial design.
ER -